IDEXX Laboratories, Inc. vs Lamb Weston Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Lamb Weston Holdings Inc trades at $47.77 (market cap $6.81B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.9× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Lamb Weston Holdings Inc for 66 Days on average.
| IDXX | LW | |
|---|---|---|
Market Cap | $40.43B | $6.81B |
Volume | 692,164 | 4,638,686 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $66.57 |
52-Week Low | $504.70 | $38.48 |
Typical Hold Time | 46 Days | 66 Days |
Enterprise Value | $41.32B | $10.61B |
Dividend Yield | — | 3.07% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Lamb Weston (LW) trades at $47.87, down 0.46% on the day, with a bullish technical signal supported by moving averages. The company shows consistent earnings beats in recent quarters, with Q3 2026 EPS of $0.75 exceeding expectations of $0.587. Revenue reached $6.45 billion in 2025, though net income margin declined to 3.85%. Analyst consensus price target stands at $53.71, representing 12% upside potential from current levels.
The stock presents a mixed outlook with strong technical momentum and earnings consistency offset by margin compression and elevated valuation at 27x P/E. Key risks include competitive pressures in the food industry and ongoing margin challenges. Institutional sentiment leans cautious with 63% hold ratings, suggesting limited near-term catalysts despite the technical bullish setup.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →